Valuation: HighTide Therapeutics, Inc.

Market Cap 1.63B 1.9B 243M 213M 201M 184M 343M 23.29B 346M 2.41B 935M 11.85B 911M 891M 38.57B P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 1.25B 1.46B 187M 164M 155M 141M 264M 17.91B 266M 1.86B 720M 9.12B 701M 685M 29.67B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
63.21%
Yield 2024 *
-
Yield 2025 -
1 day-5.13%
1 week+4.55%
Current month+4.72%
1 month-3.34%
3 months+17.67%
6 months+5.71%
Current year+12.88%
1 week 3.1
Extreme 3.105
3.64
1 month 2.96
Extreme 2.955
3.85
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 56 2010-12-31
Director of Finance/CFO 57 2022-11-30
Chief Tech/Sci/R&D Officer - 2026-02-01
Director TitleAgeSince
Chairman 56 -
Director/Board Member 44 2023-05-14
Director/Board Member 68 2020-11-29
Date Insider Type Main position Quantity % Market Cap. Importance
4/30/26 Other

Director

1,800,000 0.3151%
4/1/26 Other

Chief Executive Officer

8,325,618 1.4572%
4/1/25 Other

Chief Executive Officer

3,960,550 0.7694%
Change 5-day change 1-year change 3-year change Capi.($)
-5.13%+4.55%-18.98% - 256M
-3.30%+2.97%+54.99%+104.15% 74.18B
-0.12%-1.63%+33.14%+74.86% 59.55B
+2.71%-1.96%-13.79%+371.49% 25.84B
+0.81%+0.61%-0.49%-3.74% 24.73B
-1.05%+2.58%+24.27%-10.32% 20.87B
-1.70%-4.15%+147.82%+325.69% 15.32B
+2.15%-0.92%+48.93%+165.46% 14.06B
-0.43%-7.56%-20.10%+753.12% 13.12B
+0.04%-3.97%+20.23%+240.01% 11.85B
Average -0.60%+0.30%+27.60%+224.52% 25.98B
Weighted average by Cap. -0.72%-0.21%+35.08%+159.98%

Financials

2024 2025
Net sales - -
Net income -382M -446M -56.84M -50M -47.13M -43M -80.42M -5.46B -81.04M -566M -219M -2.78B -213M -209M -9.04B -245M -286M -36.47M -32.08M -30.24M -27.59M -51.6M -3.5B -52M -363M -141M -1.78B -137M -134M -5.8B
Net Debt -413M -482M -61.46M -54.06M -50.96M -46.49M -86.95M -5.9B -87.63M -612M -237M -3B -231M -226M -9.77B -376M -439M -55.97M -49.23M -46.41M -42.35M -79.19M -5.37B -79.81M -557M -216M -2.73B -210M -206M -8.9B
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
55
Date Price Change Volume
26-09-24 HK$3.330 -5.13% 75,500
26-09-23 HK$3.510 +3.39% 188,500
26-09-22 HK$3.395 -0.88% 387,500
26-09-21 HK$3.425 +3.79% 243,000
26-09-18 HK$3.300 +5.60% 3,673,000

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2511 Stock